141 related articles for article (PubMed ID: 36422263)
21. An
Thurakkal L; Singh S; Roy R; Kar P; Sadhukhan S; Porel M
Chem Phys Lett; 2021 Jan; 763():138193. PubMed ID: 33223560
[TBL] [Abstract][Full Text] [Related]
22. Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.
Li D; Luan J; Zhang L
Biochem Biophys Res Commun; 2021 Jan; 538():72-79. PubMed ID: 33276953
[TBL] [Abstract][Full Text] [Related]
23. Repurposing of phytomedicine-derived bioactive compounds with promising anti-SARS-CoV-2 potential: Molecular docking, MD simulation and drug-likeness/ADMET studies.
Rudrapal M; Gogoi N; Chetia D; Khan J; Banwas S; Alshehri B; Alaidarous MA; Laddha UD; Khairnar SJ; Walode SG
Saudi J Biol Sci; 2022 Apr; 29(4):2432-2446. PubMed ID: 34924801
[TBL] [Abstract][Full Text] [Related]
24. Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-
Suleimen YM; Jose RA; Mamytbekova GK; Suleimen RN; Ishmuratova MY; Dehaen W; Alsfouk BA; Elkaeed EB; Eissa IH; Metwaly AM
Plants (Basel); 2022 Aug; 11(15):. PubMed ID: 35956550
[TBL] [Abstract][Full Text] [Related]
25. Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease:
Kurniawan E; Krihariyani D
J Adv Pharm Technol Res; 2021; 12(3):298-304. PubMed ID: 34345611
[TBL] [Abstract][Full Text] [Related]
26. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
27. In Silico Analysis of Inhibiting Papain-like Protease from SARS-CoV-2 by Using Plant-Derived Peptides.
Moradi M; Golmohammadi R; Najafi A; Moosazadeh Moghaddam M; Fasihi-Ramandi M; Mirnejad R
Int J Pept Res Ther; 2022; 28(1):24. PubMed ID: 34903959
[TBL] [Abstract][Full Text] [Related]
28. Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease.
Bosken YK; Cholko T; Lou YC; Wu KP; Chang CA
Front Mol Biosci; 2020; 7():174. PubMed ID: 32850963
[TBL] [Abstract][Full Text] [Related]
29. Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2.
Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
bioRxiv; 2022 Jan; ():. PubMed ID: 35018373
[TBL] [Abstract][Full Text] [Related]
30. Cyanobacterial metabolites as promising drug leads against the M
Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
[TBL] [Abstract][Full Text] [Related]
31. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
[TBL] [Abstract][Full Text] [Related]
32. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
33. Molecular docking unveils the potential of andrographolide derivatives against COVID-19: an in silico approach.
Veerasamy R; Karunakaran R
J Genet Eng Biotechnol; 2022 Apr; 20(1):58. PubMed ID: 35420322
[TBL] [Abstract][Full Text] [Related]
34. Perceiving SARS-CoV-2 Mpro and PLpro dual inhibitors from pool of recognized antiviral compounds of endophytic microbes: an in silico simulation study.
Prajapati J; Patel R; Rao P; Saraf M; Rawal R; Goswami D
Struct Chem; 2022; 33(5):1619-1643. PubMed ID: 35431517
[TBL] [Abstract][Full Text] [Related]
35. Reconstruction of the unbinding pathways of new inhibitors of the SARS-CoV-2 papain-like protease using molecular dynamics simulation.
Rahebi P; Aryapour H
J Biomol Struct Dyn; 2023 Jul; ():1-14. PubMed ID: 37505097
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory efficacy of 2, 4-diacetylphloroglucinol against SARS-COV-2 proteins: in silico study.
Kankariya RA; Chaudhari AB; Dandi ND
Biologia (Bratisl); 2022; 77(3):815-828. PubMed ID: 35125499
[TBL] [Abstract][Full Text] [Related]
37. Molecular docking and ADMET studies of
Adegbola PI; Semire B; Fadahunsi OS; Adegoke AE
Virusdisease; 2021 Mar; 32(1):85-97. PubMed ID: 33869672
[TBL] [Abstract][Full Text] [Related]
38. Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease.
Kandeel M; Abdelrahman AHM; Oh-Hashi K; Ibrahim A; Venugopala KN; Morsy MA; Ibrahim MAA
J Biomol Struct Dyn; 2021 Sep; 39(14):5129-5136. PubMed ID: 32597315
[TBL] [Abstract][Full Text] [Related]
39. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
[TBL] [Abstract][Full Text] [Related]
40. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
